These are: (i) degree of T cell infiltrates within tumor tissue; (ii) PDL-1 expression levels; (iii) MHC expression; (iv) IFNɣ pathway activity as a measurement of how sensitive cancer cells may be to effector T-cell killing; (v) tumor mutational burden; (vi) parameters of myeloid cell-mediated inflammation, such as the C-reactive protein (CRP) and IL-6 levels, and (vii) serum lactate dehyrogenase (LDH) levels, which can be indicative of the tumor burden (Figure 1). This evidence concerns the gene HLA-C and neoplasm.